Abstract

Fibrodysplasia ossificans progressiva (FOP), a rare genetic and catastrophic disorder characterized by progressive heterotopic ossification, is caused by a point mutation, c.617G>A; p.R206H, in the activin A receptor type 1 (ACVR1) gene, one of the bone morphogenetic protein type I receptors (BMPR-Is). Although altered BMP signaling has been suggested to explain the pathogenesis, the molecular consequences of this mutation are still elusive. Here we studied the impact of ACVR1 R206H mutation on BMP signaling and its downstream signaling cascades in murine myogenic C2C12 cells and HEK 293 cells. We found that ACVR1 was the most abundant of the BMPR-Is expressed in mesenchymal cells but its contribution to osteogenic BMP signal transduction was minor. The R206H mutant caused weak activation of the BMP signaling pathway, unlike the Q207D mutant, a strong and constitutively active form. The R206H mutant showed a decreased binding affinity for FKBP1A/FKBP12, a known safeguard molecule against the leakage of transforming growth factor (TGF)-beta or BMP signaling. The decreased binding affinity of FKBP1A to the mutant R206H ACVR1 resulted in leaky activation of the BMP signal, and moreover, it decreased steady-state R206H ACVR1 protein levels. Interestingly, while WT ACVR1 and FKBP1A were broadly distributed in plasma membrane and cytoplasm without BMP-2 stimulation and then localized in plasma membrane on BMP-2 stimulation, R206H ACVR1 and FKBP1A were mainly distributed in plasma membrane regardless of BMP-2 stimulation. The impaired binding to FKBP1A and an altered subcellular distribution by R206H ACVR1 mutation may result in mild activation of osteogenic BMP-signaling in extraskeletal sites such as muscle, which eventually lead to delayed and progressive ectopic bone formation in FOP patients.

Highlights

  • The precise role of ACVR1 compared with other type I receptors in the bone morphogenetic protein (BMP) signaling pathway remains unclear

  • We found that the expression of Bmpr1a was consistently the lowest of the five BMP receptors, Bmpr2 and Acvr2a were expressed at intermediate levels, and Acvr1 was the most abundantly expressed type I receptor, at levels ϳ80-fold higher than Bmpr1a

  • A previous report revealed that ACVR1/ALK2 is the most predominantly expressed type I receptor and that the BMP receptor, type 1A (BMPR1A) shows strong activity, it has the lowest expression among the bone morphogenetic protein type I receptors (BMPR-Is) receptors in primary human mesenchymal stem cells [48]

Read more

Summary

EXPERIMENTAL PROCEDURES

Antibodies—Anti-V5 (R960-25) antibody was purchased from Invitrogen (Carlsbad, CA). Anti-Myc (9E10) anti-mouse antibody was purchased from Covance (Princeton, NJ). Plasmid Construction and Site-directed Mutagenesis—Constructs encoding full-length human ACVR1 For subsequent cloning into pcDNA6/v5-HisA, the open reading frame corresponding to ACVR1 was amplified by PCR using the above constructs as templates, with DNA primers (IDT, Coralville, IA) containing an appropriate restriction site. For the R206H mutant construct, site-directed mutagenesis using PCR was performed to induce a point mutation at nucleotide 617 using the following primer pair with mutated nucleotides underlined: BsmBIforward, 5Ј-TATGTCTTTT-AGCCTGCCTGCTGGGAGTTG-3Ј and BsmBI-reverse, 5Ј- CCAACAGTGTAATCTGGTGAGCCACTGTTCTTT-GT-3Ј and PpuMI-forward, 001105.4) wild type (WT), and its mutants5Ј-ACAAAGAACAGTGGCT-CACCAGATTACACTGTTGG-3Ј and PpuMIreverse, 5Ј-CCCAAATCTGCTATGCAACACTGTCCATTC3Ј. NM_054014.2) cDNA was amplified by PCR using cDNA from HEK293 cells as a template using the following primer pair: forward, 5Ј-TTTGGATCCGCCACCATGGGAGTGC-AGGT-3Ј, and reverse, 5Ј-TCTCGAGTCATTCCAGTTTT-AGAAGCTCCACA-3Ј, and was subcloned into pcDNA4/myc-HisA vectors. Stable C2C12 cell lines were generated by transfection with pcDNA6/v5-HisA constructs, followed by selection using 2–20 ␮g/ml Blasticidin S-containing selection medium. The RNA integrity was analyzed on a 1% native agarose gel for checking 18 S and 28 S band, and JULY 16, 2010 VOLUME 285 NUMBER 29

Activin receptor IIA
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call